DAIC

JULY 25, 2024

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

MARCH 7, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

Becker's Hospital Review - Cardiology

JANUARY 13, 2025

"CMS proposes Medicare and Medicaid coverage for implantable pulmonary artery pressure sensors to manage heart failure. Final decision to be published on Jan.

CMS 52

CMS Heart Failure Medicaid Medicare 52

Heart BMJ

JANUARY 29, 2025

Methods Using the publicly accessible Centers for Medicare and Medicaid Services Medicare Part D database and the Open Payments Database, this study assessed associations between industry-sponsored meal payments to physician prescribers and total amounts of Medicare claims and spending for sacubitril/valsartan between 2015 and 2021.

Medicare 52

Medicare Medicaid Heart Failure 52

DAIC

MAY 2, 2024

About the CardiAMP Cell Therapy Program Designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.

Ischemia 95

Ischemia Angina Heart Failure Outcomes 95

Circulation

NOVEMBER 11, 2024

Background:Tricuspid regurgitation (TR) is a common occurrence in patients with heart failure (HF), and its role in disease progression has gained attention in recent years. Circulation, Volume 150, Issue Suppl_1 , Page A4140781-A4140781, November 12, 2024.

Heart Failure 40

Heart Failure Hospital Tricuspid Medicaid 40